Equity Details
Price & Market Data
Price: $0.228
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $257,491,568
Daily Volume: 0
Performance Metrics
1 Week: 33.10%
1 Month: 56.59%
3 Months: 20.00%
6 Months: 91.44%
1 Year: 34.28%
YTD: 20.00%
About Scancell Holdings plc (SCNLF)
An extensive look into Scancell Holdings plc (SCNLF). Current price: 0.228, daily change: $0.00 / 0.00%. Market cap: 257,491,568. Performance from YTD to 1-year.
Details
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.